Manal F. Abdelmalek, M.D., focuses on understanding risk factors for acquisition and progression of metabolic dysfunction-associated steatotic liver disease. She also researches the discovery of new approaches to treat its progressive form, metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis.
Dr. Abdelmalek has expertise in clinical-translational research, and in the design and conduct of clinical trials, including investigator-initiated, industry-sponsored and National Institutes of Health-funded clinical studies. The research, trials and clinical studies she undertakes evaluate new therapies and biomarkers for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. She collaborates extensively to transition new compounds to first-in-human clinical studies and is a leading investigator in global trials of new and emerging therapies for the treatment of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.